Natural Product (NP) Details
| General Information of the NP (ID: NP1541) | |||||
|---|---|---|---|---|---|
| Name |
6-shogaol
|
||||
| Synonyms |
Shogaol; 555-66-8; [6]-Shogaol; (6)-Shogaol; enexasogaol; Trans-6-Shogaol; 23513-13-5; (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one; UNII-83DNB5FIRF; 1-(4-Hydroxy-3-methoxyphenyl)-4-decen-3-one; CHEBI:10138; Shogaol (6-Shogaol); 1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one; 83DNB5FIRF; CHEMBL25948; (4E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one; 4-DECEN-3-ONE, 1-(4-HYDROXY-3-METHOXYPHENYL)-; CCRIS 2038; 6-Shogaol (constituent of ginger) [DSC]; SCHEMBL49054; (E)-1-(4-Hydroxy-3- methoxyphenyl)dec-4-en-3-one; GTPL9773; MEGxp0_001217; Shogaol, >=90% (HPLC); 4-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl)-, (E); ACon1_001190; 4-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl)-, (4E)-; [6]-Shogaol, analytical standard; ZINC1531865; BDBM50237536; BDBM50240419; MFCD01736094; NSC752389; AKOS015888385; CCG-267210; CS-6175; MCULE-3275039845; NSC-752389; NCGC00169591-01; AS-55975; HY-14616; N2449; S9043; X1222; Y8376; A14648; C10494; 4-Decen-3-one, 1-(4-hydroxy-3-methoxyphenyl); 555S668; Q-100639; Q2746448; W-206831; BRD-K23331196-001-01-9; (E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one; [(E)-1-(4-hydroxy-3-methoxyphenyl)-dec-4-en-3-one]; 1-(4-Hydroxy-3-methoxyphenyl)-4-dodecen-3-one, 9CI
Click to Show/Hide
|
||||
| Species Origin | Acacia confusa ... | Click to Show/Hide | |||
| Acacia confusa | |||||
| Abrus precatorius | |||||
| Vachellia farnesiana | |||||
| Abelmoschus manihot | |||||
| Abrus pulchellus | |||||
| Acalypha wilkesiana | |||||
| Eleutherococcus gracilistylus | |||||
| Abutilon indicum | |||||
| Abelmoschus esculentus | |||||
| Zabelia biflora | |||||
| Abelmoschus moschatus | |||||
| Abarema clypearia | |||||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C17H24O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC
|
||||
| InChI |
1S/C17H24O3/c1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b8-7+
|
||||
| InChIKey |
OQWKEEOHDMUXEO-BQYQJAHWSA-N
|
||||
| CAS Number |
CAS 555-66-8
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ATG7 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions. | |||||
| Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Male BALB/c immunodeficient nude mice were injected with PANC-1 cells (1*107) with matrigel (100 uL) to the right flank of each mice. | |||||
| Experimental
Result(s) |
Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | |||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | DNA-binding factor KBF1 (p105) | Molecule Info | [5] | |
| Eukaryotic translation initiation factor 2A (EIF2A) | Molecule Info | [6] | ||
| PPAR-gamma (PPARG) | Molecule Info | [5] | ||
| KEGG Pathway | PPAR signaling pathway | Click to Show/Hide | ||
| 2 | AMPK signaling pathway | |||
| 3 | Osteoclast differentiation | |||
| 4 | Huntington's disease | |||
| 5 | Pathways in cancer | |||
| 6 | Transcriptional misregulation in cancer | |||
| 7 | Thyroid cancer | |||
| 8 | MAPK signaling pathway | |||
| 9 | Ras signaling pathway | |||
| 10 | cAMP signaling pathway | |||
| 11 | Chemokine signaling pathway | |||
| 12 | NF-kappa B signaling pathway | |||
| 13 | HIF-1 signaling pathway | |||
| 14 | Sphingolipid signaling pathway | |||
| 15 | PI3K-Akt signaling pathway | |||
| 16 | Apoptosis | |||
| 17 | Toll-like receptor signaling pathway | |||
| 18 | NOD-like receptor signaling pathway | |||
| 19 | RIG-I-like receptor signaling pathway | |||
| 20 | Cytosolic DNA-sensing pathway | |||
| 21 | T cell receptor signaling pathway | |||
| 22 | B cell receptor signaling pathway | |||
| 23 | TNF signaling pathway | |||
| 24 | Neurotrophin signaling pathway | |||
| 25 | Prolactin signaling pathway | |||
| 26 | Adipocytokine signaling pathway | |||
| 27 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 28 | Cocaine addiction | |||
| 29 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 30 | Shigellosis | |||
| 31 | Salmonella infection | |||
| 32 | Pertussis | |||
| 33 | Legionellosis | |||
| 34 | Leishmaniasis | |||
| 35 | Chagas disease (American trypanosomiasis) | |||
| 36 | Toxoplasmosis | |||
| 37 | Amoebiasis | |||
| 38 | Tuberculosis | |||
| 39 | Hepatitis C | |||
| 40 | Hepatitis B | |||
| 41 | Measles | |||
| 42 | Influenza A | |||
| 43 | HTLV-I infection | |||
| 44 | Herpes simplex infection | |||
| 45 | Epstein-Barr virus infection | |||
| 46 | Viral carcinogenesis | |||
| 47 | MicroRNAs in cancer | |||
| 48 | Pancreatic cancer | |||
| 49 | Prostate cancer | |||
| 50 | Chronic myeloid leukemia | |||
| 51 | Acute myeloid leukemia | |||
| 52 | Small cell lung cancer | |||
| 53 | Inflammatory bowel disease (IBD) | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| 3 | Leptin Signaling Pathway | |||
| 4 | IL5 Signaling Pathway | |||
| 5 | TCR Signaling Pathway | |||
| 6 | IL2 Signaling Pathway | |||
| 7 | TNFalpha Signaling Pathway | |||
| Panther Pathway | CCKR signaling map ST | Click to Show/Hide | ||
| 2 | Apoptosis signaling pathway | |||
| 3 | T cell activation | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Pathway Interaction Database | Noncanonical Wnt signaling pathway | Click to Show/Hide | ||
| 2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 3 | Signaling events mediated by HDAC Class I | |||
| 4 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 5 | Regulation of retinoblastoma protein | |||
| 6 | Fc-epsilon receptor I signaling in mast cells | |||
| 7 | BCR signaling pathway | |||
| 8 | LPA receptor mediated events | |||
| 9 | Atypical NF-kappaB pathway | |||
| 10 | Canonical NF-kappaB pathway | |||
| 11 | CD40/CD40L signaling | |||
| 12 | IL12-mediated signaling events | |||
| 13 | Alternative NF-kappaB pathway | |||
| 14 | Osteopontin-mediated events | |||
| 15 | Angiopoietin receptor Tie2-mediated signaling | |||
| 16 | Regulation of Telomerase | |||
| 17 | IL1-mediated signaling events | |||
| 18 | Glucocorticoid receptor regulatory network | |||
| 19 | TNF receptor signaling pathway | |||
| 20 | IL2 signaling events mediated by PI3K | |||
| 21 | Ceramide signaling pathway | |||
| 22 | amb2 Integrin signaling | |||
| 23 | IL23-mediated signaling events | |||
| 24 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 25 | EPO signaling pathway | |||
| Reactome | PPARA activates gene expression | Click to Show/Hide | ||
| 2 | Transcriptional regulation of white adipocyte differentiation | |||
| 3 | Nuclear Receptor transcription pathway | |||
| 4 | Activation of NF-kappaB in B cells | |||
| 5 | RIP-mediated NFkB activation via ZBP1 | |||
| 6 | Regulated proteolysis of p75NTR | |||
| 7 | NF-kB is activated and signals survival | |||
| 8 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 9 | FCERI mediated NF-kB activation | |||
| 10 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
| 11 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 12 | Interleukin-1 processing | |||
| 13 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
| 14 | IkBA variant leads to EDA-ID | |||
| 15 | CLEC7A (Dectin-1) signaling | |||
| 16 | CD209 (DC-SIGN) signaling | |||
| 17 | CLEC7A/inflammasome pathway | |||
| 18 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
| 19 | TRAF6 mediated NF-kB activation | |||
| WikiPathways | Wnt Signaling Pathway Netpath | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Differentiation of white and brown adipocyte | |||
| 4 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 5 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 6 | Adipogenesis | |||
| 7 | SREBP signalling | |||
| 8 | Nuclear Receptors | |||
| 9 | Toll-like receptor signaling pathway | |||
| 10 | DNA Damage Response (only ATM dependent) | |||
| 11 | SIDS Susceptibility Pathways | |||
| 12 | TCR Signaling Pathway | |||
| 13 | Notch Signaling Pathway | |||
| 14 | TGF Beta Signaling Pathway | |||
| 15 | Oxidative Stress | |||
| 16 | IL-4 Signaling Pathway | |||
| 17 | Apoptosis Modulation by HSP70 | |||
| 18 | MAPK Signaling Pathway | |||
| 19 | Myometrial Relaxation and Contraction Pathways | |||
| 20 | IL1 and megakaryotyces in obesity | |||
| 21 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 22 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 23 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
| 24 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 25 | Selenium Metabolism and Selenoproteins | |||
| 26 | Cardiac Hypertrophic Response | |||
| 27 | Cytosolic sensors of pathogen-associated DNA | |||
| 28 | Fc epsilon receptor (FCERI) signaling | |||
| 29 | Signaling by the B Cell Receptor (BCR) | |||
| 30 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 31 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 32 | EBV LMP1 signaling | |||
| 33 | Aryl Hydrocarbon Receptor | |||
| 34 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 35 | Apoptosis | |||
| 36 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 37 | BDNF signaling pathway | |||
| 38 | Integrated Pancreatic Cancer Pathway | |||
| 39 | Oncostatin M Signaling Pathway | |||
| 40 | Corticotropin-releasing hormone | |||
| 41 | AGE/RAGE pathway | |||
| 42 | TNF alpha Signaling Pathway | |||
| 43 | B Cell Receptor Signaling Pathway | |||
| 44 | TSLP Signaling Pathway | |||
| 45 | IL17 signaling pathway | |||
| 46 | Neural Crest Differentiation | |||
| 47 | TWEAK Signaling Pathway | |||
| 48 | Leptin signaling pathway | |||
| 49 | RANKL/RANK Signaling Pathway | |||
| 50 | Integrated Breast Cancer Pathway | |||
| 51 | Signalling by NGF | |||
| 52 | IL-1 signaling pathway | |||
| 53 | TCR signaling | |||
| 54 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 55 | Interleukin-1 signaling | |||
| 56 | Interleukin-1 processing | |||
| 57 | Apoptosis Modulation and Signaling | |||
| 58 | Folate Metabolism | |||
| 59 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 60 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 61 | Vitamin B12 Metabolism | |||
| 62 | Selenium Micronutrient Network | |||
| 63 | Regulation of toll-like receptor signaling pathway | |||
| 64 | Osteopontin Signaling | |||
